Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer

Cancer Research

Volumn 70, Issue 7, 2010, Pages 2644-2654

  Saito, Roy Akira ^a,b   Micke, Patrick ^c   Paulsson, Janna ^a   Augsten, Martin ^a   Peña, Cristina ^a   Jönsson, Per ^d   Botling, Johan ^c   Edlund, Karolina ^c   Johansson, Leif ^d   Carlsson, Peter ^e   Jirström, Karin ^f   Miyazono, Kohei ^b   Östman, Arne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TOKYO   (Japan)

^c UPPSALA UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FORKHEAD TRANSCRIPTION FACTOR; SCATTER FACTOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR FOXF1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; LUNG CANCER; LUNG FIBROBLAST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR PROMOTION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; FORKHEAD TRANSCRIPTION FACTORS; HEDGEHOG PROTEINS; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; NIH 3T3 CELLS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 77950844741     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3644     Document Type: Article

References (48)

1. Haviv I, Polyak K, Qiu W, Hu M, Campbell I. Origin of carcinoma associated fibroblasts. Cell Cycle 2009;8:589-95.
2. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6: 392-401.
3. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
4. Östman A, Augsten M. Cancer-associated fibroblasts and tumor growth - bystanders turning into key players. Curr Opin Genet Dev 2009;19:67-73.
5. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513-520
6. Micke P, Östman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004;45 Suppl 2:S163-75.
7. Anderberg C, Pietras K. On the origin of cancer-associated fibroblasts. Cell Cycle 2009;8:1461-1462
8. Orimo A, Weinberg RA. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther 2007;6:618-619
9. 9. Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006;5:1640-1646 (Pubitemid 46256642)
10. Massagué J. TGFβ in cancer. Cell 2008;134:215-230
11. Naber HP, ten Dijke P, Pardali E. Role of TGF-β in the tumor stroma. Curr Cancer Drug Targets 2008;8:466-472
12. 12. Stover DG, Bierie B, Moses HL. A delicate balance: TGF-β and the tumor microenvironment. J Cell Biochem 2007;101:851-861 (Pubitemid 47040867)
13. 13. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-1312 (Pubitemid 351717519)
14. 14. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007;97:247-274 (Pubitemid 46528991)
15. Anderberg C, Li H, Fredriksson L, et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 2009;69: 369-378
16. Augsten M, Hägglöf C, Olsson E, et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci U S A 2009;106: 3414-3419
17. 17. Kalinichenko VV, Lim L, Stolz DB, et al. Defects in pulmonary vasculature and perinatal lung hemorrhage in mice heterozygous null for the Forkhead Box f1 transcription factor. Dev Biol 2001 ;235: 489-506. (Pubitemid 32661187)
18. 18. Kalinichenko VV, Zhou Y, Bhattacharyya D, et al. Haploinsufficiency of the mouse Forkhead Box f1 gene causes defects in gall bladder development. J Biol Chem 2002;277:12369-12374 (Pubitemid 34952809)
19. 19. Mahlapuu M, Enerbäck S, Carlsson P. Haploinsufficiency of the forkhead gene Foxf1, a target for sonic hedgehog signaling, causes lung and foregut malformations. Development 2001;128:2397-2406 (Pubitemid 32633371)
20. Kalinichenko VV, Zhou Y, Shin B, et al. Wild-type levels of the mouse Forkhead Box f1 gene are essential for lung repair. Am J Physiol Lung Cell Mol Physiol 2002;282:L1253-65.
21. 21. Kalinichenko VV, Bhattacharyya D, Zhou Y, et al. Foxf1 +/- mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury. Hepatology 2003;37:107-117 (Pubitemid 36042151)
22. Stankiewicz P, Sen P, Bhatt SS, et al. Genomic and genic deletions of the FOX gene cluster on 16q24.1 and inactivating mutations of FOXF1 cause alveolar capillary dysplasia and other malformations. Am J Hum Genet 2009;84:780-791
23. 23. Astorga J, Carlsson P. Hedgehog induction of murine vasculogenesis is mediated by Foxf1 and Bmp4. Development 2007;134: 3753-3761 (Pubitemid 350104384)
24. Ormestad M, Astorga J, Landgren H, et al. Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development 2006;133: 833-843
25. Madison BB, McKenna LB, Dolson D, Epstein DJ, Kaestner KH. FoxF1 and FoxL1 link hedgehog signaling and the control of epithelial proliferation in the developing stomach and intestine. J Biol Chem 2009;284:5936-5944
26. Nolan-Stevaux O, Lau J, Truitt ML, et al. GLH is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009;23:24-36.
27. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461
28. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008;455:406-410
29. 29. Peterson RS, Lim L, Ye H, Zhou H, Overdier DG, Costa RH. The winged helix transcriptional activator HFH-8 is expressed in the mesoderm of the primitive streak stage of mouse embryos and its cellular derivatives. Mech Dev 1997;69:53-69. (Pubitemid 28064947)
30. Mahlapu u M, Ormestad M, Enerbäck S, Carlsson P. The forkhead transcription factor Foxf1 is required for differentiation of extra-embryonic and lateral plate mesodert Development 2001;128:155-166
31. 31. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847 (Pubitemid 28331029)
32. Pontén F, Jirström K, Uhlen M. The Human Protein Atlas-a tool for pathology. J Pathol 2008;216:387-393
33. Paulsson J, Sjöblom T, Micke P, et al. Prognostic significance of stromal platelet-derived growth factor β-receptor expression in human breast cancer. Am J Pathol 2009;175:334-341
34. 34. Malin D, Kim IM, Boetticher E, et al. Forkhead box F1 is essential for migration of mesenchymal cells and directly induces integrin-β3 expression. Mol Cell Biol 2007;27:2486-2498 (Pubitemid 46581341)
35. Nakamura T, Matsumoto K, Kiritoshi A. Tano Y, Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumorstromal interactions. Cancer Res 1997;57:3305-3313
36. 36. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-178 (Pubitemid 40616114)
37. Tingström A, Heldin CH, Rubin K. Regulation of fibroblast-mediated collagen gel contraction by platelet-derived growth factor, interleukin-1α and transforming growth factor-β1. J Cell Sci 1992;102: 315-322
38. 38. Heldin CH, Rubin K, Pietras K, Östman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-813 (Pubitemid 39331152)
39. Jiang J, Hui CC. Hedgehog signaling in development and cancer. Dev Cell 2008;15:801-812
40. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123:2229-2238
41. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432:332-337
42. 42. Fiegl H, Millinger S, Goebel G, et al. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/ neu status in primary breast cancer. Cancer Res 2006;66:29-33. (Pubitemid 43166004)
43. 43. Hanson JA, Gillespie JW, Grover A, et al. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006; 98:255-261 (Pubitemid 43264709)
44. 44. Hu M, Yao J, Cai L, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005;37:899-905. (Pubitemid 41077119)
45. 45. Patocs A, Zhang L, Xu Y, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007;357:2543-2551 (Pubitemid 350294221)
46. 46. Qiu W, Hu M, Sridhar A, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008;40:650-655 (Pubitemid 351601206)
47. Olson P, Hanahan D. Cancer. Breaching the cancer fortress. Science 2009;324:1400-1401
48. Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009;30:303-312